Diabetic retinopathy in adult patients with cystic fibrosis-related diabetes  by Yung, B. et al.
RESPIRATORY MEDICINE (1998) 92, 871-872 
Diabetic retinopathy in adult patients with cystic 
fibrosis-related diabetes 
B. YUNG”, A. LANDERS+, B. MATHALONE+, K. M. GYI” AND M. E. HODSON” 
“Department of Cystic Fibrosis, Royal Bvompton Hospital, London, U.K. 
‘Depavtmenf of Ophthalmology, Chelsea 0 Westminster Hospital, London, U.K. 
Introduction 
Cystic fibrosis-related diabetes is a well-recognized compli- 
cation in patients with cystic fibrosis. As patients with cystic 
fibrosis survive longer, the prevalence of cystic fibrosis- 
related diabetes will rise (1,2). Cystic fibrosis-related dia- 
betes has distinctive clinical and pathological features 
compared with non-cystic fibrosis-related diabetes (3). 
Microvascular complications, including diabetic retinopa- 
thy, were regarded as very rare in the past in these patients 
(4,5) and regular screening for diabetic retinopathy is not a 
universal practice in cystic fibrosis clinics in the U.K. 
Recently, cases of diabetic retinopathy have begun to 
emerge, mainly in patients with cystic fibrosis-related 
diabetes for 10 years or more (6,7). The aim of this study 
was to determine cross-sectionally the prevalence of dia- 
betic retinopathy in adult patients with cystic fibrosis- 
related diabetes for 5 yr or more who were attending a 
national cystic fibrosis centre in the U.K. 
Patients and Methods 
Thirty-four adult patients (aged 16 years or above) with 
cystic fibrosis-related diabetes for 5 yr or more attended the 
Royal Brompton Hospital Cystic Fibrosis Clinic in 
September 1996. Cystic fibrosis was diagnosed by positive 
sweat tests and typical clinical findings with or without 
genotype confirmation. Cystic fibrosis-related diabetes was 
diagnosed by repeated raised random or fasting blood 
glucose and/or oral glucose tolerance test. Two of the 34 
patients were unable to participate in this study due to work 
commitments. Of the remaining 32 patients, two were living 
abroad and underwent ophthalmic examinations by oph- 
thalmologists locally. Another patient was too unwell to be 
examined but she had recently undergone ophthalmic 
examination by her local optician. The results of these three 
patients’ examinations were obtained. The remaining 29 
patients were examined by experienced ophthalmologists 
between September 1996 and March 1997. Each patient 
underwent slit-lamp biomicroscopy with 78 and 90 dioptre 
indirect lenses. The patients’ pupils were dilated with 1% 
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Tropicamide. Blood samples were obtained for the 
measurement of glycosylated haemoglobin within 3 weeks 
of their eye examinations. The levels of glycosylated hae- 
moglobin were determined by Ion Capture Assay method 
(Abbott Laboratories, U.S.A.). All 32 patients received 
insulin for their diabetes and were pancreatic insufficient, 
requiring pancreatic enzyme supplementation. Continuous 
variables were summarized with median and range. Differ- 
ences between groups were tested with the Mann-Whitney 
test. This study has the local ethics committee’s approval 
and written or informed consents were obtained from all 
patients examined. 
Results 
The median age of the patients examined was 27 years 
(range: 19-43 years) and the median duration of diabetes 
was 9 years (range: 5-29 years). There was an equal sex 
distribution. Five patients were found to have diabetic 
retinopathy (see Table 1). The prevalence of diabetic retin- 
opathy for patients with diabetes for 5 yr or more and 10 yr 
or more were 16% (five of 31 patients) and 23% (three of 13 
patients), respectively. None of the eight patients who had 
had diabetes between 5 and 6 yr were found to have 
diabetic retinopathy. Glycosylated haemoglobin levels were 
not significantly different between the groups of patients 
with and without diabetic retinopathy (median HbAlc 
6.2% ds 7.3%, respectively, P=O.25). 
Discussion 
We found a high prevalence of diabetic retinopathy in our 
patients with cystic fibrosis-related diabetes, particularly in 
those who had diabetes for 10 yr or more. In patients with 
insulin-dependant diabetes mellitus, tight glycaemic control 
delays the onset and slows the progression of clinically 
important retinopathy (8). This may also apply to patients 
with cystic fibrosis-related diabetes. No significant differ- 
ence in the glycosylated haemoglobin levels was found 
between our patients with and without diabetic retinopathy 
but the number of patients studied was relatively small. It is 
clear from our study that cystic fibrosis-related diabetic 
retinopathy should no longer be regarded as rare. This 
complication should be screened for at least annually, by 
individuals experienced in the diagnosis of diabetic retin- 
opathy, particularly in those patients with diabetes for 5 yr 
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TABLE 1. Characteristics of the adult cystic fibrosis patients with diabetic retinopathy 
Case Age/sex 
Duration Family Retina Glycosylated 
of diabetes history of examination haemoglobin 
(v-1 diabetes findings (normal: ~6.2%) 
1 35 F 23 Yes Proliferative retinopathy 8.8 
2 34M 12 No Maculopathy 5.6 
3 29 M 12 No Background retinopathy 7.4 
4 21 M 9 No Background retinopathy 6.2 
5 21 F 7 No Background retinopathy 6.0 
or more. Early treatment and regular follow-up can then be 
given in order to prevent the retinopathy-related visual 
impairment and/or blindness. 
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